ReviewLancet (London, England)2021
Urgent lessons from COVID 19: why the world needs a standing, coordinated system and sustainable financing for global research and development.
Review in Lancet (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed.
- Indirect protection and long-term effectiveness of inactivated COVID-19 vaccine: a stepped-wedge randomised trial in Serrana, Brazil.Scientific reports · 2026Trial
- Review
- Malaria in the 21st Century: Global Disease Burden, Epidemiological Insights, and Strategic Control Approaches.Biology · 2026Review
- Innovations in reagent manufacturing to support the global diagnostics supply chain.Frontiers in public health · 2026Article
- Article
- Organoids at the forefront of global health: accelerated research and ethical implications in the cases of Zika and COVID-19.Global public health · 2025Article
- PEARLES challenges and solutions to the implementation of clinical research responses to epidemics and pandemics: a scoping review.EClinicalMedicine · 2025Review
- Principal investigators' experience of COVID-19 therapeutic clinical trials in Japan: a qualitative study.BMJ open · 2025Article
- Article
- How to build a better clinical trial ecosystem for future infectious disease emergencies in Japan: Findings from a narrative review and stakeholder meetings.Global health & medicine · 2025Review
- Financing for pandemic preparedness and response measures: a systematic scoping review.Bulletin of the World Health Organization · 2024Article
- Molecular mimicry of SARS-COV-2 antigens as a possible natural anti-cancer preventive immunization.Frontiers in immunology · 2024Article
- Treating COVID-19: Targeting the Host Response, Not the Virus.Life (Basel, Switzerland) · 2023Review
- Vaccine Innovation Meta-Model for Pandemic Contexts.Journal of pharmaceutical innovation · 2023Article
- The pandemic veneer: COVID-19 research as a mobilisation of collective intelligence by the global research community.Collective intelligence · 2023Article
- Human health implications of emerging diseases and the current situation in India's vaccine industry.Science in One Health · 2023Review
- Unveiling patenting strategies of therapeutics and vaccines: evergreening in the context of COVID-19 pandemic.Frontiers in medicine · 2023Article
- Global outlook of the multiplier effect of research and development on environmental sustainability.PloS one · 2023Article
- One Health timeliness metrics to track and evaluate outbreak response reporting: A scoping review.EClinicalMedicine · 2022Article
- Challenges and response to pandemics as seen in a One Health perspective.Science in One Health · 2022Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The research and development (R&D) ecosystem has evolved over the past decade to include pandemic infectious diseases, building on experience from multiple recent outbreaks. Outcomes of this evolution have been particularly evident during the COVID-19 pandemic with accelerated development of vaccines and monoclonal antibodies, as well as novel clinical trial designs. These products were developed, trialled, manufactured, and authorised for use in several countries within a year of the pandemic's onset. Many gaps remain, however, that must be bridged to establish a truly efficient and effective end-to-end R&D preparedness and response ecosystem. Foremost among them is a global financing system. In addition, important changes are required for multiple aspects of enabling sciences and product development. For each of these elements we identify priorities for improved and faster functionality. There will be no better time than now to seriously address these needs, however difficult, as the ravages of COVID-19 continue to accelerate with devastating health, social, and economic consequences for the entire community of nations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.